Table_1_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.xlsx by Ryousuke Kasai (14577584)

“…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”

DataSheet_1_GSDMD contributes to myocardial reperfusion injury by regulating pyroptosis.pdf by Xiaomiao Ye (13850284)

“…Moreover, compared with WT mice, GSDMD^-/- mice showed reduced infarct size (25.45 ± 3.07% versus 36.47 ± 3.72%), improved left ventricular ejection fraction (37.71 ± 1.81% versus 29.44 ± 2.28%) and left ventricular fractional shortening (18.01 ± 0.97% versus 13.62 ± 1.15%) as well as attenuated pathological damage after I/R injury, along with reduced levels of proinflammatory cytokines and decreased infiltration of neutrophils.…”

Image_3_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.jpeg by Ryousuke Kasai (14577584)

“…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”

Image_6_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.jpeg by Ryousuke Kasai (14577584)

“…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”

Image_2_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.jpeg by Ryousuke Kasai (14577584)

“…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”

Image_1_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.jpeg by Ryousuke Kasai (14577584)

“…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”

Image_5_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.jpeg by Ryousuke Kasai (14577584)

“…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”

Image_4_Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.jpeg by Ryousuke Kasai (14577584)

“…Furthermore, three months following the second immunization, the proportion of high responders among patients with MDs decreased significantly compared to that among patients without MDs (p-value of less than 0.01). …”

Image_8.tif by Angelica Martins Batista (5086820)

“…After logistic regression analysis with adjustment for the covariates gender and ethnicity, CCL5 −403 (rs2107538) CT heterozygotes (OR = 0.5, P-value = 0.04) and T carriers (OR = 0.5, P-value = 0.01) were associated with protection against CCC. …”

Image_1.tif by Angelica Martins Batista (5086820)

“…After logistic regression analysis with adjustment for the covariates gender and ethnicity, CCL5 −403 (rs2107538) CT heterozygotes (OR = 0.5, P-value = 0.04) and T carriers (OR = 0.5, P-value = 0.01) were associated with protection against CCC. …”

Image_5.tif by Angelica Martins Batista (5086820)

“…After logistic regression analysis with adjustment for the covariates gender and ethnicity, CCL5 −403 (rs2107538) CT heterozygotes (OR = 0.5, P-value = 0.04) and T carriers (OR = 0.5, P-value = 0.01) were associated with protection against CCC. …”

Image_3.tif by Angelica Martins Batista (5086820)

“…After logistic regression analysis with adjustment for the covariates gender and ethnicity, CCL5 −403 (rs2107538) CT heterozygotes (OR = 0.5, P-value = 0.04) and T carriers (OR = 0.5, P-value = 0.01) were associated with protection against CCC. …”

Image_9.tif by Angelica Martins Batista (5086820)

“…After logistic regression analysis with adjustment for the covariates gender and ethnicity, CCL5 −403 (rs2107538) CT heterozygotes (OR = 0.5, P-value = 0.04) and T carriers (OR = 0.5, P-value = 0.01) were associated with protection against CCC. …”

Image_2.tif by Angelica Martins Batista (5086820)

“…After logistic regression analysis with adjustment for the covariates gender and ethnicity, CCL5 −403 (rs2107538) CT heterozygotes (OR = 0.5, P-value = 0.04) and T carriers (OR = 0.5, P-value = 0.01) were associated with protection against CCC. …”

Image_6.tif by Angelica Martins Batista (5086820)

“…After logistic regression analysis with adjustment for the covariates gender and ethnicity, CCL5 −403 (rs2107538) CT heterozygotes (OR = 0.5, P-value = 0.04) and T carriers (OR = 0.5, P-value = 0.01) were associated with protection against CCC. …”

Image_4.tif by Angelica Martins Batista (5086820)

“…After logistic regression analysis with adjustment for the covariates gender and ethnicity, CCL5 −403 (rs2107538) CT heterozygotes (OR = 0.5, P-value = 0.04) and T carriers (OR = 0.5, P-value = 0.01) were associated with protection against CCC. …”

Data_Sheet_1.docx by Angelica Martins Batista (5086820)

“…After logistic regression analysis with adjustment for the covariates gender and ethnicity, CCL5 −403 (rs2107538) CT heterozygotes (OR = 0.5, P-value = 0.04) and T carriers (OR = 0.5, P-value = 0.01) were associated with protection against CCC. …”

Image_7.tif by Angelica Martins Batista (5086820)

“…After logistic regression analysis with adjustment for the covariates gender and ethnicity, CCL5 −403 (rs2107538) CT heterozygotes (OR = 0.5, P-value = 0.04) and T carriers (OR = 0.5, P-value = 0.01) were associated with protection against CCC. …”

Image_3_Transcriptome Analysis of Effects of Folic Acid Supplement on Gene Expression in Liver of Broiler Chickens.pdf by Yujie Zhang (399434)

“…Finally, contents of LPL, PPARγ, and FAS in abdominal fat were decreased with the folic acid supplmented diets (P < 0.01). …”

Table_1_Transcriptome Analysis of Effects of Folic Acid Supplement on Gene Expression in Liver of Broiler Chickens.DOCX by Yujie Zhang (399434)

“…Finally, contents of LPL, PPARγ, and FAS in abdominal fat were decreased with the folic acid supplmented diets (P < 0.01). …”